Getting to Grips with Grants

Share this article:
Providers are wrestling most with the way pharmaceutical companies have restructured their grant procedures, according to MM&M's annual survey of medical education firms. A majority (60%) of the 68 respondents to the question this year referred to grantors' formal mechanisms for reviewing grants as being their greatest challenge. That's a big change from last year, when only one in 10 companies cited grant-request requirements as major hurdle.

“Navigating the new grant processes, which differ from company to company” was a familiar refrain among this group, whose struggles fell into three key areas: the overall review process (58%); the inconsistency between review systems (32%); and managing time lines (10%).

The changing regulatory climate continues to have a vexing effect, with 19% of the 68 firms citing the grantor's response to various rules and guidelines as their main bugaboo.

The way grantors insist on separating promotional education from other activities irked others. “Med ed companies are often relegated to one project or another, and this undermines the strategic impact of a strong med ed plan,” one provider lamented.

Of the 57 firms that commented on grant approval times, 82% said the process is taking longer, by anywhere from six weeks to nine months, with a mere 7% reporting shorter times. “Companies with sound grant processes are faster; those with new or developing processes are slower,” commented one respondent.

Despite these inconveniences, many indicated commercial support is up. Of 56 respondents to this question, 41% reported a rise in funding. One noted sponsors “remain committed” to “cutting-edge” education. Others suggested that grantors' unease with compliance issues may be wearing off. Still, a number continue to struggle with tighter budgets. One in four noted a decline, while 34% said funding was unchanged.

As for the types of activities being funded, many firms commented on a trend toward Web-based programs developed in multiple formats, though most say live events continue to be the industry standard.

All data taken from responses to open questions. Not a scientific analysis.

Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.